Journal of Gastroenterology

, Volume 48, Issue 10, pp 1180–1187

Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis

  • Hee Yeon Kim
  • Jong Young Choi
  • Chung-Hwa Park
  • Myeong Jun Song
  • Do Seon Song
  • Chang Wook Kim
  • Si Hyun Bae
  • Seung Kew Yoon
  • Young Joon Lee
  • Sung Eun Rha
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

Estimating liver parenchymal enhancement prior to gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance (MR) imaging is crucial to accurate detection and characterization of focal hepatic lesions. We aimed to clarify the factors predictive of liver enhancement in a relatively large sample of patients.

Methods

Gd-EOB-DTPA-enhanced MR images of 328 patients with liver cirrhosis (Child–Pugh class A in 223 patients, class B in 71 patients, and class C in 34 patients) were analyzed retrospectively. The liver parenchymal signal intensity (SI) was measured in pre-contrast T1-weighted images and hepatocyte phase images. The relative enhancement (RE) was calculated: (hepatocyte phase SI–pre-contrast SI)/pre-contrast SI. We analyzed the correlation between hepatic function parameters and RE.

Results

RE of patients with Child–Pugh A cirrhosis was significantly higher than that of patients with Child–Pugh B or C cirrhosis (both P < 0.001). Among various clinical factors, platelet count, prothrombin activity, albumin, sodium, total bilirubin, aspartate aminotransferase, Model for End-stage Liver Disease (MELD) score, MELD-Na score, Child–Pugh score, and the presence of ascites were significantly correlated with RE. A multiple stepwise regression analysis revealed that MELD-Na, albumin, and the presence of ascites were the only factors that predicted liver parenchymal enhancement on hepatocyte-phase images.

Conclusion

The degree of liver parenchymal enhancement after Gd-EOB-DTPA administration was correlated with liver function parameters. Gd-EOB-DTPA-enhanced MR images require careful interpretation, particularly in patients with cirrhosis and clinical factors such as high MELD-Na score, hypoalbuminemia, or ascites.

Keywords

Gd-EOB-DTPA Liver cirrhosis Liver function Magnetic resonance imaging 

Abbreviations

Gd-EOB-DTPA

Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid

MR

Magnetic resonance

HCC

Hepatocellular carcinoma

SI

Signal intensity

ROI

Region of interest

RE

Relative enhancement ratio

AST

Aspartate aminotransferase

ALT

Alanine aminotransferase

MELD

Model for end stage liver disease

MELDNa

Model for end stage liver disease-sodium

ICG

Indocyanine green

References

  1. 1.
    Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology. 2005;237:89–98.PubMedCrossRefGoogle Scholar
  2. 2.
    Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol. 2009;44:793–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457–67.PubMedCrossRefGoogle Scholar
  4. 4.
    Park G, Kim YK, Kim CS, Yu HC, Hwang SB. Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol. 2010;83:1010–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Raman SS, Leary C, Bluemke DA, Amendola M, Sahani D, McTavish JD, et al. Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr. 2010;34:163–72.PubMedCrossRefGoogle Scholar
  6. 6.
    Saito K, Moriyasu F, Sugimoto K, Nishio R, Saguchi T, Nagao T, et al. Diagnostic efficacy of gadoxetic acid-enhanced MRI for hepatocellular carcinoma and dysplastic nodule. World J Gastroenterol. 2011;17:3503–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol. 2011;21:2056–66.PubMedCrossRefGoogle Scholar
  8. 8.
    Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging–correlation with molecular transporters and histopathologic features. Radiology. 2010;256:817–26.PubMedCrossRefGoogle Scholar
  9. 9.
    Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol. 2010;20:2405–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Clément O, Mühler A, Vexler V, Berthezène Y, Brasch RC. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. Invest Radiol. 1992;27:612–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Higaki A, Tamada T, Sone T, Kanki A, Sato T, Tanimoto D, et al. Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging. Magn Reson Imaging. 2012;30:689–93.PubMedCrossRefGoogle Scholar
  12. 12.
    Chen BB, Hsu CY, Yu CW, Wei SY, Kao JH, Lee HS, et al. Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol. 2012;22:171–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Yamada A, Hara T, Li F, Fujinaga Y, Ueda K, Kadoya M, et al. Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology. 2011;260:727–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Tamada T, Ito K, Higaki A, Yoshida K, Kanki A, Sato T, et al. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol. 2011;80:e311–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Kim HY, Choi JY, Kim CW, Bae SH, Yoon SK, Lee YJ, et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis. Liver Transpl. 2012;18:850–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Kim AY, Kim YK, Lee MW, Park MJ, Hwang J, Lee MH, et al. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis. Acta Radiol. 2012;53:830–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Kubota K, Tamura T, Aoyama N, Nogami M, Hamada N, Nishioka A, et al. Correlation of liver parenchymal gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid enhancement and liver function in humans with hepatocellular carcinoma. Oncol Lett. 2012;3:990–4.PubMedGoogle Scholar
  18. 18.
    Tajima T, Takao H, Akai H, Kiryu S, Imamura H, Watanabe Y, et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2010;34:362–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30:1042–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–26.PubMedCrossRefGoogle Scholar
  22. 22.
    Hamm B, Staks T, Muhler A, Bollow M, Taupitz M, Frenzel T, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785–92.PubMedGoogle Scholar
  23. 23.
    Reimer P, Rummeny EJ, Shamsi K, Balzer T, Daldrup HE, Tombach B, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996;199:177–83.PubMedGoogle Scholar
  24. 24.
    Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, Weishaupt D. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol. 2008;18:1577–86.PubMedCrossRefGoogle Scholar
  25. 25.
    van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther. 1999;290:153–7.PubMedGoogle Scholar
  26. 26.
    Ryeom HK, Kim SH, Kim JY, Kim HJ, Lee JM, Chang YM, et al. Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol. 2004;5:231–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Somsouk M, Guy J, Biggins SW, Vittinghoff E, Kohn MA, Inadomi JM. Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Aliment Pharmacol Ther. 2009;30:741–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Matsumata T, Kanematsu T, Yoshida Y, Furuta T, Yanaga K, Sugimachi K. The indocyanine green test enables prediction of postoperative complications after hepatic resection. World J Surg. 1987;11:678–81.PubMedCrossRefGoogle Scholar
  29. 29.
    Kitano S, Kim YI. ICG clearance in assessing cirrhotic patients with hepatocellular carcinoma for major hepatic resection. HPB Surg. 1997;10:182–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Hee Yeon Kim
    • 1
  • Jong Young Choi
    • 1
  • Chung-Hwa Park
    • 1
  • Myeong Jun Song
    • 1
  • Do Seon Song
    • 1
  • Chang Wook Kim
    • 1
  • Si Hyun Bae
    • 1
  • Seung Kew Yoon
    • 1
  • Young Joon Lee
    • 2
  • Sung Eun Rha
    • 2
  1. 1.Division of Hepatology, Department of Internal Medicine, College of MedicineThe Catholic University of KoreaSeoulKorea
  2. 2.Department of Radiology, College of MedicineThe Catholic University of KoreaSeoulKorea

Personalised recommendations